Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:243-244 (2 August), doi:10.1136/bmj.327.7409.243
May not be necessary
| The first 150 words of the full text of this article appear below. |
BCG vaccination is effective against forms of tuberculosis that occur commonly in childhood that have a high morbidity and mortality, such as tuberculous meningitis.1 2 Current guidelines for the United Kingdom recommend tuberculin skin testing before BCG vaccination for all children older than 3 months.3 The evidence base for this recommendation is unclearno randomised controlled trials have been conducted to compare outcome of BCG vaccination with and without prior tuberculin skin testing, and the resulting two or three stage procedure seriously compromises uptake.
The BCG vaccine was not available in the United Kingdom from 9 August 2002when all stocks from the monopoly supplier, Evans Vaccines, were declared potentially ineffective by the Medicines Control Agency and the Department of Healthuntil supplies from Denmark's State Serum Institute became accessible during December 2002. The currently available BCG vaccine is for intradermal use only. From November 1998 to July 2001 a similar loss of supply
Graham H Bothamley, lead physician for tuberculosis
North East London Tuberculosis Network, Homerton University Hospital, London E9 6SR
Ed Cooper, consultant paediatrician
Partnership for Child Development, Department of Infectious Disease Epidemiology, St Mary's Campus, Imperial College, London W2 1PF
Delane Shingadia, senior lecturer in paediatrics
Queen Mary College Westfield, London E1 4NS
Alex Mellanby, consultant in communicable disease control
Health Protection Agency, London E1 1RD
Read all Rapid Responses